GB201714307D0 - Treatment of neurodegenerative diseases - Google Patents
Treatment of neurodegenerative diseasesInfo
- Publication number
- GB201714307D0 GB201714307D0 GBGB1714307.4A GB201714307A GB201714307D0 GB 201714307 D0 GB201714307 D0 GB 201714307D0 GB 201714307 A GB201714307 A GB 201714307A GB 201714307 D0 GB201714307 D0 GB 201714307D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- neurodegenerative diseases
- neurodegenerative
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1714307.4A GB201714307D0 (en) | 2017-09-06 | 2017-09-06 | Treatment of neurodegenerative diseases |
PCT/GB2018/052514 WO2019048852A1 (en) | 2017-09-06 | 2018-09-05 | Treatment of neurodegenerative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1714307.4A GB201714307D0 (en) | 2017-09-06 | 2017-09-06 | Treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201714307D0 true GB201714307D0 (en) | 2017-10-18 |
Family
ID=60050741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1714307.4A Ceased GB201714307D0 (en) | 2017-09-06 | 2017-09-06 | Treatment of neurodegenerative diseases |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201714307D0 (en) |
WO (1) | WO2019048852A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202016710D0 (en) * | 2020-10-21 | 2020-12-02 | Univ Birmingham | Treatment of eye conditions |
GB202016708D0 (en) * | 2020-10-21 | 2020-12-02 | Univ Birmingham | Uses of chk2 inhibitors |
WO2023212411A1 (en) * | 2022-04-29 | 2023-11-02 | Indiana University Research And Technology Corporation | Methods of treating neuropathy using foretinib and compositions thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201516905D0 (en) * | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
-
2017
- 2017-09-06 GB GBGB1714307.4A patent/GB201714307D0/en not_active Ceased
-
2018
- 2018-09-05 WO PCT/GB2018/052514 patent/WO2019048852A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019048852A1 (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006746B (en) | Methods of treatment | |
IL269106A (en) | Methods of treating neurodegenerative diseases | |
EP3227330C0 (en) | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases | |
IL265902A (en) | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases | |
GB201804514D0 (en) | Treatment of pyroptosis | |
EP3273955A4 (en) | Treatment of respiratory diseases | |
ZA201903003B (en) | Treatment of neurological diseases | |
GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
HK1258994A1 (en) | Methods for treatment of diseases | |
GB201412578D0 (en) | Treatment of neurological diseases | |
GB201804515D0 (en) | Treatment of necroptosis | |
GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
EP3606522C0 (en) | Novel treatment of mitochondrial diseases | |
EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
EP3534954A4 (en) | Compounds for treatment of neurodegenerative diseases | |
RS64273B1 (en) | Treatment of mitochondrial diseases | |
GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
GB201714316D0 (en) | Treatement of neurodegenerative diseases | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
EP3426280A4 (en) | Methods of treating neurodegenerative diseases | |
GB201704666D0 (en) | Treatment of neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |